Anti-viral pyrimidine nucleoside analogues

US2016244476A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016244476-A1
Application numberUS-201615141992-A
CountryUS
Kind codeA1
Filing dateApr 29, 2016
Priority dateApr 17, 2000
Publication dateAug 25, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A compound of formula (I) wherein Ar can be one six-membered or two fused six-membered aromatic rings; R 8 and R 9 can be hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyoxy, aryloxy, thiol, alkylthiol, arythiol, or aryl; Q can be O, S or CY 2 , where Y may be H, alkyl or halogens; X can be O, NH, S, N-alkyl, (CHR 2 ) m where m is 1 to 10, and CY 2 ; Z can be O, S, NH, or N-alkyl; U″ is H and U′ can be H or CH 2 ; wherein: T can be OH, H, halogens, O-alkyl, O-acyl, O-aryl, CN, NH 2 or N 3 ; T′ and T″ can be H or halogen; and W can be H or a phosphate group. Compounds show anti-viral activity, for example with respect to varicella zoster virus.

First claim

Opening claim text (preview).

What is claimed is: 1 . A compound having the formula: wherein Ar is an, optionally substituted, aromatic ring system, the aromatic ring system comprising one six-membered aromatic ring or two fused six-membered aromatic rings; R 8 and R 9 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkoxy, aryloxy, thiol, alkylthiol, arylthiol, and aryl; Q is selected from the group consisting of O, S and CY 2 , where Y may be the same or different and is selected from H, alkyl and halogens; X is selected from the group consisting of O, NH, S, N-alkyl, (CH 2 ) m where m is 1 to 10, and CY 2 where Y may be the same or different and is selected from hydrogen, alkyl and halogens; Z is selected from the group consisting of O, S, NH, and N-alkyl; U″ is H and U′ is selected from H and CH 2 T, or U′ and U″ are joined so as to form a ring moiety including Q wherein U′-U″ together is respectively selected from the group consisting of —CTH—CT′T″ and —CT′=CT′—, so as to provide ring moieties selected from the group consisting of: wherein: T is selected from the group consisting of OH, H, halogens, a-alkyl, a-acyl, a-aryl, CN, NH 2 and N 3 ; T′ is selected from the group consisting of H and halogens and, where more than one T′ is present, they may be the same or different; T″ is selected from the group consisting of H and halogens; and W is selected from the group consisting of H, a phosphate group and a pharmacologically acceptable salt, derivative or pro-drug thereof; with the provisos that: (1) when T is OAc and T′ and T″ are present and are H, Ar is not 4-(2-benzoxazolyl)phenyl; and (2) when Q, X and Z are each 0, and R 8 , R 9 , T′, T″ and W are each H and T is OH or O-acyl, Ar is: one six-membered carbocyclic aromatic ring substituted by one or more moieties independently selected from the group consisting of alkyl, aryl, cycloalkyl, chlorine, bromine, iodine, cyano, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio and arylthio, any of which alkyl, cycloalkyl or aryl moieties may be substituted by one or more members selected from the group consisting of chlorine, bromine, iodine, CN, CO 2 alkyl (C 1 to C 6 ), CONH 2 , CONH alkyl (C 1 to C 6 ), SR, S alkyl (C 1 to C 6 ) and NO 2 ; one six-membered aromatic ring system which contains one, two, three or four hetero atoms and which ring system may be optionally substituted; or two fused six-membered aromatic rings, which may be optionally substituted. 2 . A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient. 3 . A method of prophylaxis or treatment of a viral infection comprising administering to a patient in need of such treatment an effective dose of a compound of claim 1 .

Assignees

Inventors

Classifications

  • Antivirals · CPC title

  • Pyrrolo-pyrimidine radicals · CPC title

  • containing six-membered rings with nitrogen as a ring hetero atom · CPC title

  • Ortho-condensed systems · CPC title

  • with the saccharide radical esterified by phosphoric or polyphosphoric acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016244476A1 cover?
A compound of formula (I) wherein Ar can be one six-membered or two fused six-membered aromatic rings; R 8 and R 9 can be hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyoxy, aryloxy, thiol, alkylthiol, arythiol, or aryl; Q can be O, S or CY 2 , where Y may be H, alkyl or halogens; X can be O, NH, S, N-alkyl, (CHR 2 ) m where m is 1 to 10, and CY 2 ;…
Who is the assignee on this patent?
Rega Found, Univ College Cardiff Consultants Ltd
What technology area does this patent fall under?
Primary CPC classification C07H19/24. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Aug 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).